Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-3476(73)80135-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer.
Curr Treat Options Oncol
January 2025
The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Colorectal cancer is the third leading cause of cancer death worldwide. In China, the incidence and mortality of colorectal cancer are increasing, in which low rectal cancer is more common. Ultra-low rectal cancer refers to rectal cancer where the distance between the tumor and the anus is less than 5 cm, it accounts for about 70%-80% of rectal tumors.
View Article and Find Full Text PDFImaging paediatric bone marrow in immunocompromised patients.
Pediatr Radiol
January 2025
Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid, 28009, Spain.
The bone marrow of immunocompromised patients may exhibit abnormalities due to the underlying disease, adverse treatment effects, and/or complications arising from either source. Such complexity poses a significant diagnostic challenge, particularly in children. Magnetic resonance imaging (MRI) is the modality of choice when evaluating bone marrow in these patients.
View Article and Find Full Text PDFFirst-in-Human Phase 1 study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors.
Clin Cancer Res
January 2025
Institute of Cancer Research, Sutton, Sutton, United Kingdom.
Purpose: Innate immune cell-based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on natural killer (NK) cells/macrophages and EGFR on tumor cells, redirecting antitumor activity towards tumors. The safety and tolerability of AFM24 was evaluated in this Phase 1/2a dose escalation/dose expansion study in patients with recurrent or persistent, advanced solid tumors known to express EGFR.
View Article and Find Full Text PDFSafety and Efficacy of a 48-Month Efinaconazole 10% Solution Treatment/Maintenance Regimen: 24-Month Daily Use Followed by 24-Month Intermittent Use.
Infect Dis Rep
January 2025
Mediprobe Research Inc., London, ON N5X 2P1, Canada.
Background/objectives: In an 18- to 24-month Treatment Phase with once-daily efinaconazole 10% solution, subjects with onychomycosis showed an increased rate of cure at Month 24 versus the phase III trials. In order to further improve efficacy, we initiated an extended intermittent efinaconazole Maintenance Phase with use 2-3 times weekly for an additional 24 months from Month 24 to Month 48. These are the first data presented for a 48-month efinaconazole use period.
View Article and Find Full Text PDFEmpowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals.
Pharmacy (Basel)
December 2024
Department of Pharmacy, School of Medicine, University of Split, 21000 Split, Croatia.
Despite technological advancements, healthcare professionals must actively prioritize patient safety. Reporting adverse drug reactions is a critical aspect of this responsibility, and the most accessible healthcare providers, community pharmacists, and pharmacy technicians play a key role. Therefore, this study assessed their knowledge and practices regarding adverse drug reaction reporting in Croatia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!